NF279

NF279 (1-100 μM; 10 min) potently inhibits human NTPDase1, NTPDase2, NTPDase3, and NTPDase8, with the highest potency against human NTPDase3 (IC₅₀ 0.6 μM) and the lowest potency against human NTPDase8 ATPase activity (IC₅₀ 36 μM)^[2].
NF279 (1-100 μM; 10 min) potently inhibits mouse NTPDase1, NTPDase2, NTPDase3, and NTPDase8, with the highest potency against mouse NTPDase2 (IC₅₀ 3.3 μM) and the lowest potency against mouse NTPDase1 ATPase activity (IC₅₀ 52 μM)^[2].
NF279 (20 µM) reduces GABA-activated currents in isolated primary rat hippocampal pyramidal neurons to a mean of 61.8% of control, with a reversible inhibitory effect^[3].
NF279 (3-300 nM; 10 s pre-incubation; 1-30 µM; simultaneous co-application) potently and reversibly inhibits rat P2X1 receptors expressed in Xenopus laevis oocytes, with an IC₅₀ of 19 nM following 10 s pre-incubation, and shows reduced potency (IC₅₀ 2.02 µM) when co-applied with ATP^[4].
NF279 (0.3-10 µM; 10 s pre-incubation; 10-300 µM; simultaneous co-application) reversibly inhibits rat P2X3 receptors expressed in Xenopus laevis oocytes, with an IC₅₀ of 1.62 µM following 10 s pre-incubation, and shows greatly reduced potency (IC₅₀ 85.5 µM) when co-applied with ATP^[4].
NF279 (1-10 µM; simultaneous co-application; post-activation application) acts as a reversible, competitive antagonist of rat P2X2 receptors expressed in Xenopus laevis oocytes, with an IC₅₀ of 0.76 µM and a K_B value of 0.36 µM derived from Schild analysis^[4].
NF279 shows very low potency against human P2X4 receptors expressed in Xenopus laevis oocytes, with less than 50% inhibition at 300 µM and an IC₅₀ greater than 300 µM^[4].
NF279 (10-50 μM; 90 min) dose-dependently inhibits X4-tropic, R5-tropic, and dual-tropic HIV-1 fusion with TZM-bl cells without affecting cell viability or VSV-G-mediated fusion, with greater potency against HXB2 Env-mediated fusion^[5].
NF279 (30 μM; 90 min) dose-dependently inhibits X4-tropic HIV-1 fusion with CEM-A cells without affecting cell viability, with lower potency than observed in TZM-bl cells^[5].
NF279 (30 μM; 90 min) potently inhibits X4-tropic and R5-tropic HIV-1 fusion with TZM-bl cells^[5].
NF279 (30 μM; 10 min preincubation) acts as a dual CXCR4/CCR5 antagonist by completely blocking chemokine-mediated calcium signaling in TZM-bl cells^[5].
NF279 (30 μM; 10 min preincubation) blocks gp120-mediated CXCR4 activation by inhibiting calcium signaling in TZM-bl cells^[5].
NF279 (30 μM; 10 min preincubation) acts as a partial CXCR4 antagonist and blocks CXCR3/CXCR7 signaling by inhibiting chemokine-mediated calcium flux in CEM-A cells^[5].
NF279 (0-50 μM; 90 min) inhibits R5-tropic HIV-1 fusion with both wild-type CCR5-expressing TZM-bl cells and CCR5^G163R mutant-expressing JGR.H11 cells, with greater potency against the mutant coreceptor (IC₅₀ = 4.5 μM for JGR.H11 cells, 13.3 μM for TZM-bl cells)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.